Fluorinated Compounds Labelled with 18F as Radiopharmaceuticals

  • L. Procházka Department of Radiopharmaceuticals, Institute of Nuclear Physics, Academy of Sciences of the Czech Republic, Řež near Prague,
  • M. Kropáček Department of Radiopharmaceuticals, Institute of Nuclear Physics, Academy of Sciences of the Czech Republic, Řež near Prague,
  • M. Mirzajevová Department of Radiopharmaceuticals, Institute of Nuclear Physics, Academy of Sciences of the Czech Republic, Řež near Prague,
  • J. Zimová Department of Radiopharmaceuticals, Institute of Nuclear Physics, Academy of Sciences of the Czech Republic, Řež near Prague,
  • M. Försterová Department of Radiopharmaceuticals, Institute of Nuclear Physics, Academy of Sciences of the Czech Republic, Řež near Prague,
  • H. Švecová Department of Radiopharmaceuticals, Institute of Nuclear Physics, Academy of Sciences of the Czech Republic, Řež near Prague,
  • F. Melichar Department of Radiopharmaceuticals, Institute of Nuclear Physics, Academy of Sciences of the Czech Republic, Řež near Prague,
  • O. Bělohlávek Department of Nuclear Medicine and Positron Emission Tomography Centre, Hospital Homolka, Prague

Abstrakt

Radiopharmaceuticals labelled with 18F are the most studied compounds in nuclear medicine, especially for positron emission tomography (PET). Recent studies are engaged in developing new compounds for PET, which should be more specific in certain processes than the widespread 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG). Novel radiopharmaceutical compounds trace cell metabolism, such as protein synthesis, amino acid transport, or nucleoside synthesis. Several promising fluorinated compounds are introduced.
Publikované
2010-01-15
Sekce
Články